ScienceMed®

Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials

Psiquiatria
Imagem de arquivo, ilustrativa — não é do estudo. Tratografia por ressonância magnética: fibras nervosas do cérebro humano. jgmarcelino · CC BY 2.0 · Wikimedia Commons

MetanáliseNível 1 · Evidência consolidadaJournal of affective disorders30 jun 202356 citações

Salvar

Resumo original em inglês

O que aconteceu

The concurrent assessment of weight and affective psychopathology outcomes relevant to the psychopharmacology of major eating disorders (EDs), namely anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), warrants systematic review and meta-analysis of randomized controlled trials (RCTs).

PubMed, Scopus, and ClinicalTrials.gov were inquired from inception through August 31st, 2022, for RCTs documenting any psychopharmacological intervention for EDs diagnosed according to validated criteria and reporting weight and psychopathology changes. Adopted keywords were: "anorexia nervosa," "bulimia nervosa," "binge eating disorder," "antidepressant," "antipsychotic," and "mood stabilizer." No language restriction applied.

O que encontraram

5122 records were identified, and 203 full-texts were reviewed. Sixty-two studies entered the qualitative synthesis (AN = 22, BN = 23, BED = 17), of which 22 entered the meta-analysis (AN = 9, BN = 10, BED = 3). Concerning BMI increase in AN, olanzapine outperformed placebo (Hedges'g = 0.283, 95%C·I. = 0.051-0.515, I2 = 0 %; p = .017), whereas fluoxetine failed (Hedges'g = 0.351, 95%C.I. = -0.248 to 0.95, I2 = 63.37 %; p = .251). Fluoxetine not significantly changed weight (Hedges'g = 0.147, 95%C.I. = -0.157-0.451, I2 = 0 %; p = .343), reducing binging (Hedges'g = 0.203, 95%C.I. = 0.007-0.399, I2 = 0 %; p = .042), and purging episodes (Hedges'g = 0.328, 95%C.I. = -0.061-0.717, I2 = 58.97 %; p = .099) in BN. Lisdexamfetamine reduced weight (Hedges'g = 0.259, 95%C.I. = 0.071-0.446, I2 = 0 %; p = .007) and binging (Hedges'g = 0.571, 95%C.I. = 0.282-0.860, I2 = 53.84 %; p < .001) in BED.

Por que isso importa

The efficacy of different drugs varies across different EDs, warranting additional primary studies recording broad psychopathological and cardiometabolic outcomes besides weight, especially against established psychotherapy interventions.

O que ainda não sabemos

Small sample size, short duration, and lack of reliable operational definitions affect most of the included sponsored RCTs.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials

Michele Fornaro, Anna Maria Mondin, Martina Billeci, Andrea Fusco, Michele De Prisco, Claudio Caiazza, Fausta Micanti, Raffaella Calati, Andre Ferrer Carvalho, Andrea de Bartolomeis

Descritores MeSH

  • Binge-Eating Disorder
  • Feeding and Eating Disorders
  • Antipsychotic Agents
  • Bulimia Nervosa
  • Anorexia Nervosa
  • Psychopharmacology
  • Fluoxetine
  • Humans
  • Randomized Controlled Trials as Topic

Veja também